Challenges in the electrophysiology and Watchman businesses led the medtech company to cut its sales and earnings per share forecasts for the second quarter in a row.
Boston Scientific again cuts 2026 guidance
Challenges in the electrophysiology and Watchman businesses led the medtech company to cut its sales and earnings per share forecasts for the second quarter in a row.